

NCTN Breast Cancer Trials Portfolio (Open as of 11/15/2022)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Neoadjuvant	Post-Neoadjuvant	Adjuvant	Metastatic
<div data-bbox="142 284 451 479" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>EA1181 (COMPASS-pCR) HER2+ Stage II and IIIa</p> </div>	<div data-bbox="571 284 997 430" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>NRG-BR005 Any HR/HER2 status</p> </div> <div data-bbox="571 479 997 625" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>S1706 Any HR/HER2 status Inflammatory; No mets</p> </div> <div data-bbox="571 665 997 860" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>A011801 (COMPASS-RD) HER2+ T1-4, N0-3 Any HR-; If HR+, node+</p> </div>	<div data-bbox="1134 284 1438 430" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>CCTG MA.39 HR+/HER2- Low risk; Node positive</p> </div> <div data-bbox="1134 479 1438 665" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>NRG-BR007 (DEBRA) HR+/HER2- pT1(<=2cm) pN0M0</p> </div>	<div data-bbox="1575 276 2005 422" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>EA1183 (FEATURE) HR+ Bone-dominant (BD) or bone-only (BO) disease</p> </div> <div data-bbox="1575 479 2005 592" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>S2007 HER2- Brain metastases</p> </div> <div data-bbox="1617 657 1984 771" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>EAY131 (MATCH)</p> </div> <div data-bbox="1617 836 1984 950" style="border: 1px solid black; padding: 5px; text-align: center;"> <p>S1609 (DART)</p> </div>

Legend by Subtype Status

White =
Any HR/HER2
status

Blue = HER2-
(Any HR status)

Orange = HER2+
(Any HR status)

Purple =
HR+ and HER2-

Yellow = HR+
(Any HER2 status)

Pink = Cross-
disease trials

NCTN Breast Cancer Trials (Open as of 11/15/2022)

Protocol Number	Phase	Protocol Title
A011801	III	The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
CCTG MA.39	III	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
EA1181	II	EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)
EA1183	II	FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
NRG-BR005	II	A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
NRG-BR007	III	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score \leq 18 Breast Cancer (DEBRA)
S1706	II	A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
S2007	II	A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
EAY131	II	Molecular Analysis for Therapy Choice (MATCH)
S1609	II	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>